All Stories

Polish biotech Ryvu waves goodbye to 30% of staff in focus on phase 3 blood cancer trials

Ryvu Therapeutics is shrinking its headcount by 30% as the Polish biotech focuses its funds on taking its lead blood cancer drug through phase 3 trials.

Feb 25, 2025 - 16:11
 0
Polish biotech Ryvu waves goodbye to 30% of staff in focus on phase 3 blood cancer trials
Ryvu Therapeutics is shrinking its headcount by 30% as the Polish biotech focuses its funds on taking its lead blood cancer drug through phase 3 trials.
Read More

Tags:

Previous Article

LG begins mass production of its 40-inch P2P car display

Next Article

Kiniksa adds to Sjögren’s exodus with trial termination, axes AstraZeneca asset

Related Posts

Septerna drops lead asset over bilirubin side effects 4 months after going public

Septerna drops lead asset over bilirubin side effects 4...

Feb 18, 2025  0

Deerfield sues to stop Alcon’s 'unrelenting campaign' to take over Aurion

Deerfield sues to stop Alcon’s 'unrelenting campaign' t...

Feb 24, 2025  0

Fierce Biotech Layoff Tracker 2025: Moderna lays off 50 employees; Kojin to close

Fierce Biotech Layoff Tracker 2025: Moderna lays off 50...

Feb 14, 2025  0